Basic and clinical studies of meropenem in the urological field

Kazuhiro Hata, Tadasu Takenaka, Satoshi Uno, Yoshio Nishitani, Daisuke Yamada, Toshihide Hayashi, Noriaki Ono, Masaya Tugawa, Hiromi Kumon, Hiroyuki Ohmori, Yoshikatsu Kondou, Katsuichi Nanba, Teruaki Akaeda

Research output: Contribution to journalArticlepeer-review


We studied the antibacterial activity and clinical efficacy of meropenem, a new carbapenem antibiotic, in the urological field. 1) Antibacterial activity: We measured the MICs of MEPM against clinical isolates (206 strains of 14 species) from urinary tract infections, and compared them with those of imipenem (IPM), ceftazidime and latamoxef. In general, the antibacterial activities of MEPM were almost equal to those of IPM but superior to those of other control drugs. 2) Clinical efficacy: According to the criteria of the Japanese UTI Committee, the overall clinical efficacy rate was 72.2% (13/18) for chronic complicated UTI. Bacteriologically 19 of 23 strains (82.6%) were eradicated. 3) Side effects: No clinical side effects were observed. Concerning laboratory findings, a transient elevation of GOT, GPT and LDH, and decline of Na and Cl in one case and an elevation of BUN and sCr in one case each were noted.

Original languageEnglish
Pages (from-to)607-614
Number of pages8
Publication statusPublished - Apr 1992


  • Meropenem

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Basic and clinical studies of meropenem in the urological field'. Together they form a unique fingerprint.

Cite this